IMMUNE CHECKPOINT INHIBITOR SALVAGE THERAPY IN PATIENT WITH REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Vol. 65 No. 2 (2019), CLINICAL CASE
Vol. 65 No. 2 (2019)

IMMUNE CHECKPOINT INHIBITOR SALVAGE THERAPY IN PATIENT WITH REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

CLINICAL CASE
https://doi.org/10.37469/0507-3758-2019-65-2-294-297
Published 01.02.2019
Kirill Lepik
Pavlov First St. Petersburg State Medical University, R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation
Aleksey Polushin
Pavlov First St. Petersburg State Medical University, R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation
Ye. Kondakova
Pavlov First St. Petersburg State Medical University, R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation
K. Yakimovich
Pavlov First St. Petersburg State Medical University, R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation
I. Tsygankov
Pavlov First St. Petersburg State Medical University, R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation
A. Gavrilenko
Pavlov First St. Petersburg State Medical University, R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation
Yu. Zalyalov
Pavlov First St. Petersburg State Medical University, R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation
B. Afanasev
Pavlov First St. Petersburg State Medical University, R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation
Nataliya Mikhaylova
Pavlov First St. Petersburg State Medical University, R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation
##article.numberofdownloads## 60
##article.numberofviews## 92
PDF (Русский)

Keywords

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
IMMUNOTHERAPY
NIVOLUMAB

How to Cite

Lepik, K., Polushin, A., Kondakova, Y., Yakimovich, K., Tsygankov, I., Gavrilenko, A., Zalyalov, Y., Afanasev, B., & Mikhaylova, N. (2019). IMMUNE CHECKPOINT INHIBITOR SALVAGE THERAPY IN PATIENT WITH REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Voprosy Onkologii, 65(2), 294–297. https://doi.org/10.37469/0507-3758-2019-65-2-294-297
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

Despite the progress in the therapy of a primary central nervous system lymphoma (PCNSL) the rates of disease relapse and resistance to therapy are high. Development of new effective therapeutic strategies is needed. One of the key mechanisms in the pathogenesis of PCNSL is the suppression of the immune response in the tumor microenvironment. Recent studies have demonstrated the increased expression of PD-L1 in the tumor cells of PCNSL and therefore the use of PD-1 blockade might be effective. This report includes the description of a case of the successful use of PD-1 inhibitor nivolumab as monotherapy in a severely pretreated young patient with refractory PCNSL.
https://doi.org/10.37469/0507-3758-2019-65-2-294-297
##article.numberofdownloads## 60
##article.numberofviews## 92
PDF (Русский)

References

Комратова К.А., Абугова Ю.Г., Озеров С.С. и др. Первичная диффузная в-крупноклеточная лимфома центральной нервной системы (клинический случай и обзор литературы) // онкогематология. - 2017. - Т 12. - № 1. - С. 10-16.

Chapuy B., Roemer M.G.M., Stewart C. et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas // Blood. - 2016. - Т 127. - № 7. - С. 869-881.

Ferreri A.J.M., Blay J.Y, Reni M. et al. Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience // J. Clin. Oncol. - 2003. - Т 21. - № 2. - С. 266-272.

Ferreri A.J., Reni M., Foppoli M. et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial // Lancet. - 2009. - Т 374. - № 9700. - С. 1512-1520.

Ferreri J.M., Ferreri A.J.M. How I treat primary CNS lymphoma // Blood. - 2011. - Т 118. - № 3. - С. 510-522.

Harder H., Holtel H., Bromberg J.E.C. et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. // Neurology. - 2004. - Т. 62. - № 4. - С. 544-547.

Nayak L., Iwamoto F.M., Lacasce A. et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma // Blood. -2017. - Т 129. - № 23. - С. 3071-3073.

Nguyen P L., Chakravarti A., Finkelstein D.M. et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma // J. Clin. Oncol. - 2005. - Т. 23. - № 7. - С. 1507-1513.

O'Neill B.P., Decker P.A., Tieu C. et al. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma // Am. J. Hematol. - 2013. - Т 88. - № 12. - С. 997-1000.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2019

Most read articles by the same author(s)